北米子宮がん診断市場
Market Size in USD Billion
CAGR :
% 
 予測期間 |
2024 –2030 |
 市場規模（基準年） |
|
 Market Size (Forecast Year) |
USD 7,946.03 |
 CAGR |
% |
| 主要市場プレーヤー |
北米子宮がん診断市場、診断タイプ別（機器ベースおよび手順ベース）、タイプ別（子宮内膜がんおよび子宮肉腫）、年齢グループ別（30歳未満、31〜40歳、41〜50歳、51〜60歳、60歳以上）、エンドユーザー別（病院、診断センター、がん研究センター、外来手術センター、専門クリニックなど）、流通チャネル別（直接入札、サードパーティ販売業者など） - 2030年までの業界動向および予測。
北米子宮がん診断市場の分析と洞察
子宮がんは、女性の生殖器系で発生する最も一般的ながんです。子宮細胞で発生し、他の部位に転移する悪性腫瘍です。米国がん協会 (ACS) の調査によると、子宮肉腫は世界中の子宮がんの 5% を占め、子宮内膜がんは子宮がんの最も一般的な形態です。
Data Bridge Market Research の分析によると、北米の子宮がん診断市場は、予測期間中に 11.2% の CAGR で成長し、2030 年までに 79 億 4,603 万米ドルに達する見込みです。北米の女性人口の肥満率の上昇と子宮がん患者の増加により、診断タイプが市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (2020～2015年にカスタマイズ可能) |
|
定量単位 |
売上高（百万米ドル）、販売数量（個数）、価格（米ドル） |
|
対象セグメント |
診断タイプ（機器ベースおよび手順ベース）、タイプ（子宮内膜がんおよび子宮肉腫）、年齢グループ（<30、31〜40、41〜50、51〜60、および>60）、エンドユーザー（病院、診断センター、がん研究センター、外来手術センター、専門クリニックなど）、流通チャネル（直接入札、サードパーティの販売業者など）別 |
|
対象国 |
米国、カナダ、メキシコ |
|
対象となる市場プレーヤー |
F-Hoffmann La Roche Ltd.、Siemens Healthcare Private Limited、Narang Medical Limited、ESAOTE SPA、Olympus Corporation、Arquer Diagnostics Ltd、Guzip Biomarkers Corporation、General Electric、Canon Medical Systems ANZ Pty Limited、KARL STORZ、Medtronic、Stryker、Surtex Instruments Limited、Koninklijke Philips NV、FUJIFILM Corporation、AED、Jalal Surgical、Integra LifeSciences、B. Braun Melsungen AG、GRAIL など |
北米子宮がん診断市場の定義
Diagnosis of uterine cancer includes ultrasound, biopsy procedures and blood tests. Ultrasound tests use sound waves and produce images of the ovaries and uterus. Two types of ultrasound are included in diagnostic testing for uterine cancer: abdominal ultrasound and transvaginal ultrasound. An abdominal scan test involves scanning the full bladder with a small probe across the abdomen, while a transvaginal scan involves inserting a probe tube into the vagina to scan or create an image. Biopsy procedures include endometrial biopsy, hysteroscopy and dilation and curettage.
Cancer is one of the leading causes of death worldwide and the prevalence of this disease has increased at an alarming rate. Therefore, health professionals are focusing on developing effective screening and treatment solutions to control obesity rates. Moreover, an endometrial biopsy involves removing some malignant tissue from the endometrium and sending it for a testing procedure. The growing number of geriatric women in the U.S. is also a major factor contributing to the growth of the uterine cancer diagnostic market.
North America Uterine Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail below:
Drivers
- Technological advancements in uterine cancer diagnostics
Uterine cancer is a ubiquitous gynaecological disease with many tests available for diagnosis, which include pelvic examination, endometrial biopsy, Dilation and Curettage (D&C), Transvaginal ultrasound, Computed Tomography (CT or CAT) scan, Magnetic Resonance Imaging (MRI) and biomarker testing of the tumor. Traditional means of detecting and monitoring cancers rely largely on imaging and, where possible, blood-based protein biomarkers, many of which are non-specific. Most cases of uterine cancer are diagnosed at late stages, as the presenting symptoms are often non-specific. The signs and symptoms of uterine cancer vary from person to person, making it difficult to provide accurate early diagnosis. This calls for personalized diagnostic plans, which involve multiple diagnostic tests.
Thus, technological advancements in uterine cancer diagnostics are expected to drive the market's growth.
- Rising demand for minimally invasive advanced screening techniques
Uterine cancer, especially endometrial cancer, is the fifth most common cancer in women in very high human development index regions based on age-standardized rates and its incidence has increased over the last few years. The standard strategy to diagnose endometrial cancer consists of office-based pelvic ultrasonography plus endometrial papilla sampling in cases of increased endometrial thickness. A hysteroscopy is recommended when the diagnosis is uncertain. Limitations include sample insufficiency in unsuccessful insertions (on occasions due to cervical stenosis or prolapse) and as well an abnormal sonographic appearance of the endometrium. Hence several limitations are associated with so-called standard methods of a uterine cancer diagnosis.
Thus, rising demand for minimally invasive advanced screening techniques are expected to drive the market's growth.
Restraint
- High risk complications during diagnostic tests
Several screening tests are used for detecting uterine cancers, which include the PAP test, transvaginal ultrasound and endometrial sampling (biopsy) among others. Although these tests are considered standard for diagnosing uterine cancer, they have their associated risks, including false-negative and false-positive results and side effects such as bleeding, discomfort, infection and puncture of the uterus.
As mentioned above, many complications are associated with the current diagnostic and screening tests for uterine cancer, which are keeping patients at further risk. These risks are expected to restrain the growth of the North America uterine cancer diagnostics market.
Opportunity
- Increasing prevalence of uterine cancer
Uterine cancer is the most common type of gynecologic cancer. Over 90% of uterine cancers begin in the endometrium, the tissue lining the uterus. As the prevalence is increasing, the introduction of promising new treatments and therapeutic biologics and the rapid growth of hormone-resistant cancer drugs due to fewer side effects are also increasing. Awareness of the incidence of uterine cancer is growing among patients and healthcare providers, who are now becoming more active in learning about the diagnosis and treatments available for these diseases, which is expected to act as an opportunity for the market's growth.
Rates of new uterine cancer cases have risen 0.6% per year from 2010-2019 and death rates have risen an average of 1.7% per year for the /corp.html">same time frame. As the uterine cancer patient rate is increasing, the use of treatments and advanced technologies for cancer diagnosis will increase, which is an opportunity for market growth.
Challenge
- Lack of diagnostic infrastructure
Non-communicable diseases such as uterine cancer and other types of cancer have now been recognized by the United Nations and WHO as major public health crises. Cancer is the biggest part of this problem and health systems face a major challenge to improve cancer care, control costs and increase system efficiency. Differences in treatment approaches and outcomes between high-income countries and low and middle-income countries are striking. Reasons for this disparity include cost, access to care, workforce and training gaps and lack of awareness among the lay and medical community. Diagnosis and treatment play an important role in this complex environment. Different regions and countries of the world have different health systems, but most of them are fragmented or poorly coordinated. There is an urgent need to expand cancer care in low- and middle-income countries.
Post-COVID-19 Impact on North America Uterine Cancer Diagnostics Market
The COVID-19 pandemic has caused disruptions in elective health services related to uterine screening, pre-cancer care and management of abnormal screening results. This could lead to an increase in the incidence of uterine cancer, exacerbating existing health inequalities.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launches and strategic partnerships to improve the technology and test results involved in the North America uterine cancer diagnostics market.
Recent Developments
- In November 2022, Koninklijke Philips N.V., announced the North America launch of a next-generation compact portable ultrasound solution at the Radiological Society of North America (RSNA) annual meeting to bring the diagnostic quality associated with premium cart-based ultrasound systems to more patients. it is portable and versatile with good image quality or performance. it is compatible with Philips ultrasound systems Affiniti and EPIQ transducer. This has helped the company to expand its product portfolio
- In April 2022, Medtronic and GE Healthcare announced a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs). Because of this collaboration, customers can access extensive product portfolios, financial solutions and exceptional service. GE Healthcare Interventional Imaging solutions are built to help our customers deliver care at a higher level for patients, which is very useful of cancer patients. This has helped the company to expand its business
North America Uterine Cancer Diagnostics Market Scope
North America uterine cancer diagnostics market is segmented into diagnostic type, type, age group, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
BY DIAGNOSTIC TYPE
- Instrument Based
- Procedure Based
On the basis of diagnostic type, the North America uterine cancer diagnostic market is segmented into instrument based and procedure based.
BY TYPE
- Endometrial Cancer
- Uterine Sarcoma
On the basis of type, the North America uterine cancer diagnostic market is segmented into endometrial cancer and uterine sarcoma.
BY AGE GROUP
- <30 years
- 31-40 years
- 41-50 years
- 51-60 years
- >60 years
On the basis of age group, the North America uterine cancer diagnostic market is segmented into <30, 31-40, 41-50, 51-60 and >60.
BY END USER
- Hospitals
- Diagnostic Centers
- Cancer Research Centers
- Ambulatory Surgical Centers
- Specialized Clinics
- Others
On the basis of end user, the North America uterine cancer diagnostic market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, specialized clinics and others.
BY DISTRIBUTION CHANNEL
- Direct Tenders
- Third Party Distributors
- Others
On the basis of distribution channel, the North America uterine cancer diagnostic market is segmented into direct tender, third party distributors and others.
North America Uterine Cancer Diagnostics Market Regional Analysis/Insights
The North America uterine cancer diagnostics market is analyzed and market size information is provided diagnostic type, type, age group, end user and distribution channel.
The countries covered in this market report are the U.S., Canada, and Mexico.
U.S is expected to dominate the North America uterine cancer diagnostics market due to the presence of key market players in the largest consumer market with high GDP and due to its latest advanced cancer diagnostic technology and inventions in uterine cancer diagnostics.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and North America Uterine Cancer Diagnostics Market Share Analysis
北米の子宮がん診断市場の競争状況は、競合他社ごとに詳細を提供します。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、北米の子宮がん診断市場への会社の重点にのみ関連しています。
北米の子宮がん診断市場で活動している主要企業としては、F-Hoffmann La Roche Ltd.、Siemens Healthcare Private Limited、Narang Medical Limited、ESAOTE SPA、Olympus Corporation、Arquer Diagnostics Ltd、Guzip Biomarkers Corporation、General Electric、Canon Medical Systems ANZ Pty Limited、KARL STORZ、Medtronic、Stryker、Surtex Instruments Limited、Koninklijke Philips NV、FUJIFILM Corporation、AED、Jalal Surgical、Integra LifeSciences、B. Braun Melsungen AG、GRAIL などがあります。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 INSTRUMENT BASED LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 PATENT ANALYSIS OF NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET
4.4 REIMBURSEMENT SCENARIO
4.5 INDUSTRY INSIGHTS:
4.6 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.7 PRICING STRATEGIES
4.8 CONCLUSION
4.9 PREVALENCE, INCIDENCE, AND MORTALITY RATE OF UTERINE CANCER
4.1 COST OF UTERINE CANCER PROCEDURE
5 REGULATORY FRAMEWORK
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 TECHNOLOGICAL ADVANCEMENTS IN UTERINE CANCER DIAGNOSTICS
6.1.2 RISING DEMAND FOR MINIMALLY INVASIVE ADVANCED SCREENING TECHNIQUES
6.1.3 RISING AWARENESS TOWARDS UTERINE CANCER
6.1.4 RISING IMPORTANCE OF WOMEN'S HEALTH
6.2 RESTRAINTS
6.2.1 HIGH RISK COMPLICATIONS DURING DIAGNOSTIC TESTS
6.2.2 LACK OF SKILLED PROFESSIONALS FOR PROPER DIAGNOSIS OF UTERINE CANCER
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF UTERINE CANCER
6.3.2 RISE IN ADOPTION OF SEDENTARY LIFESTYLE
6.3.3 GROWTH IN MENSTRUAL COMPLICATIONS
6.4 CHALLENGES
6.4.1 LACK OF DIAGNOSTIC INFRASTRUCTURE
6.4.2 HIGH COST OF IMAGING SYSTEMS
7 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
7.1 OVERVIEW
7.2 INSTRUMENT-BASED
7.2.1 ULTRASOUND SCANNING
7.2.1.1 SYSTEMS
7.2.1.2 ABDOMINAL ULTRASOUND SCANNING
7.2.1.3 TRANSVAGINAL ULTRASOUND SCANNING
7.2.1.4 ACCESSORIES
7.2.2 IMAGING DEVICES
7.2.2.1 CT/PET (POSITRON EMISSION TOMOGRAPHY) SCAN
7.2.2.2 MAGNETIC RESONANCE IMAGING (MRI)
7.2.2.3 COMPUTED TOMOGRAPHY (CT) SCAN
7.2.2.4 OTHERS
7.2.3 TESTS
7.2.3.1 BLOOD TESTS
7.2.3.1.1 COMPLETE BLOOD COUNT
7.2.3.1.2 CA125 MARKER BLOOD TEST
7.2.3.2 URINE TESTS
7.2.3.3 OTHER TESTS
7.2.4 OTHERS
7.3 PROCEDURE BASED
7.3.1 ENDOMETRIAL BIOPSY
7.3.2 HYSTEROSCOPY
7.3.3 DILATION & CURETTAGE
7.3.4 CYSTOSCOPY
7.3.5 PROCTOSCOPY
7.3.6 OTHERS
8 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE
8.1 OVERVIEW
8.2 ENDOMETRIAL CANCER
8.2.1 SEROUS ADENOCARCINOMA
8.2.1.1 INSTRUMENT-BASED
8.2.1.1.1 ULTRASOUND SCANNING
8.2.1.1.2 IMAGING DEVICES
8.2.1.1.3 TESTS
8.2.1.1.4 OTHERS
8.2.1.2 PROCEDURE-BASED
8.2.1.2.1 ENDOMETRIAL BIOPSY
8.2.1.2.2 HYSTEROSCOPY
8.2.1.2.3 DILATION & CURETTAGE
8.2.1.2.4 CYSTOSCOPY
8.2.1.2.5 PROCTOSCOPY
8.2.1.2.6 OTHERS
8.2.2 ADENOSQUAMOUS CARCINOMA
8.2.2.1 INSTRUMENT-BASED
8.2.2.1.1 ULTRASOUND SCANNING
8.2.2.1.2 IMAGING DEVICES
8.2.2.1.3 TESTS
8.2.2.1.4 OTHERS
8.2.2.2 PROCEDURE-BASED
8.2.2.2.1 ENDOMETRIAL BIOPSY
8.2.2.2.2 HYSTEROSCOPY
8.2.2.2.3 DILATION & CURETTAGE
8.2.2.2.4 CYSTOSCOPY
8.2.2.2.5 PROCTOSCOPY
8.2.2.2.6 OTHERS
8.2.3 UTERINE CARCINOSARCOMA
8.2.3.1 INSTRUMENT-BASED
8.2.3.1.1 ULTRASOUND SCANNING
8.2.3.1.2 IMAGING DEVICES
8.2.3.1.3 TESTS
8.2.3.1.4 OTHERS
8.2.3.2 PROCEDURE-BASED
8.2.3.2.1 ENDOMETRIAL BIOPSY
8.2.3.2.2 HYSTEROSCOPY
8.2.3.2.3 DILATION & CURETTAGE
8.2.3.2.4 CYSTOSCOPY
8.2.3.2.5 PROCTOSCOPY
8.2.3.2.6 OTHERS
8.2.4 PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM
8.2.4.1 INSTRUMENT-BASED
8.2.4.1.1 ULTRASOUND SCANNING
8.2.4.1.2 IMAGING DEVICES
8.2.4.1.3 TESTS
8.2.4.1.4 OTHERS
8.2.4.2 PROCEDURE-BASED
8.2.4.2.1 ENDOMETRIAL BIOPSY
8.2.4.2.2 HYSTEROSCOPY
8.2.4.2.3 DILATION & CURETTAGE
8.2.4.2.4 CYSTOSCOPY
8.2.4.2.5 PROCTOSCOPY
8.2.4.2.6 OTHERS
8.3 UTERINE SARCOMA
8.3.1 LEIOMYOSARCOMA
8.3.1.1 INSTRUMENT-BASED
8.3.1.1.1 ULTRASOUND SCANNING
8.3.1.1.2 IMAGING DEVICES
8.3.1.1.3 TESTS
8.3.1.1.4 OTHERS
8.3.1.2 PROCEDURE-BASED
8.3.1.2.1 ENDOMETRIAL BIOPSY
8.3.1.2.2 HYSTEROSCOPY
8.3.1.2.3 DILATION & CURETTAGE
8.3.1.2.4 CYSTOSCOPY
8.3.1.2.5 PROCTOSCOPY
8.3.1.2.6 OTHERS
8.3.2 ENDOMETRIAL STROMAL SARCOMA
8.3.2.1 INSTRUMENT-BASED
8.3.2.1.1 ULTRASOUND SCANNING
8.3.2.1.2 IMAGING DEVICES
8.3.2.1.3 TESTS
8.3.2.1.4 OTHERS
8.3.2.2 PROCEDURE-BASED
8.3.2.2.1 ENDOMETRIAL BIOPSY
8.3.2.2.2 HYSTEROSCOPY
8.3.2.2.3 DILATION & CURETTAGE
8.3.2.2.4 CYSTOSCOPY
8.3.2.2.5 PROCTOSCOPY
8.3.2.2.6 OTHERS
8.3.3 UNDIFFERENTIATED SARCOMA
8.3.3.1 INSTRUMENT-BASED
8.3.3.1.1 ULTRASOUND SCANNING
8.3.3.1.2 IMAGING DEVICES
8.3.3.1.3 TESTS
8.3.3.1.4 OTHERS
8.3.3.2 PROCEDURE-BASED
8.3.3.2.1 ENDOMETRIAL BIOPSY
8.3.3.2.2 HYSTEROSCOPY
8.3.3.2.3 DILATION & CURETTAGE
8.3.3.2.4 CYSTOSCOPY
8.3.3.2.5 PROCTOSCOPY
8.3.3.2.6 OTHERS
9 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP
9.1 OVERVIEW
9.2 >60 YEARS
9.3 51-60 YEARS
9.4 41-50 YEARS
9.5 31-40 YEARS
9.6 <30 YEARS
10 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 DIAGNOSTIC CENTERS
10.4 CANCER RESEARCH CENTERS
10.5 AMBULATORY SURGICAL CENTERS
10.6 SPECIALIZED CLINICS
10.7 OTHERS
11 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TENDER
11.3 THIRD PARTY DISTRIBUTORS
11.4 OTHERS
12 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY REGION
12.1 NORTH AMERICA
12.1.1 U.S.
12.1.2 CANADA
12.1.3 MEXICO
13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 KONINKLIJKE PHILIPS N.V.
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPMENTS
15.2 CANON MEDICAL SYSTEMS ANZ PTY LIMITED.
15.2.1 COMPANY SNAPSHOT
15.2.2 COMPANY SHARE ANALYSIS
15.2.3 PRODUCT PORTFOLIO
15.2.4 RECENT DEVELOPMENTS
15.3 GENERAL ELECTRIC COMPANY
15.3.1 COMPANY SNAPSHOT
15.3.2 REVENUE ANALYSIS
15.3.3 COMPANY SHARE ANALYSIS
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPMENTS
15.4 SIEMENS HEALTHCARE GMBH
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENTS
15.5 FUJIFILM CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.6 AED.MD
15.6.1 COMPANY SNAPSHOT
15.6.2 PRODUCT PORTFOLIO
15.6.3 RECENT DEVELOPMENTS
15.7 ARQUER DIAGNOSTICS LTD
15.7.1 COMPANY SNAPSHOT
15.7.2 PRODUCT PORTFOLIO
15.7.3 RECENT DEVELOPMENTS
15.8 B. BRAUN SE
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ESAOTE SPA
15.9.1 COMPANY SNAPSHOT
15.9.2 PRODUCT PORTFOLIO
15.9.3 RECENT DEVELOPMENTS
15.1 F. HOFFMANN-LA ROCHE LTD
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENTS
15.11 GRAIL
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENTS
15.12 GUZIP BIOMARKERS CORPORATION
15.12.1 COMPANY SNAPSHOT
15.12.2 PRODUCT PORTFOLIO
15.12.3 RECENT DEVELOPMENTS
15.13 INTEGRA LIFESCIENCES
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENTS
15.14 JALAL SURGICAL
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 KARL STORZ SE & CO. KG
15.15.1 COMPANY SNAPSHOT
15.15.2 PRODUCT PORTFOLIO
15.15.3 RECENT DEVELOPMENTS
15.16 MEDTRONIC
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENTS
15.17 NARANG MEDICAL LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.18 OLYMPUS CORPORATION
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENTS
15.19 STRYKER
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENTS
15.2 SURTEX INSTRUMENTS LIMITED.
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENTS
16 QUESTIONNAIRE
17 RELATED REPORTS
表のリスト
TABLE 1 NORTH AMERICA RATE OF ENDOMETRIAL CANCER (2020)
TABLE 2 U.S. (2022)
TABLE 3 U.K. (2019)
TABLE 4 GERMANY RATE OF ENDOMETRIAL CANCER (2019)
TABLE 5 POLAND RATE OF ENDOMETRIAL CANCER (2020)
TABLE 6 SINGAPORE (2020)
TABLE 7 JAPAN (2022)
TABLE 8 INDIA (2020)
TABLE 9 AUSTRALIA (2022)
TABLE 10 BRAZIL RATE OF ENDOMETRIAL CANCER (2018)
TABLE 11 ARGENTINA (2020)
TABLE 12 UAE (2020)
TABLE 13 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 18 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 20 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 22 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA >60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA 51-60 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA 41-50 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA 31-40 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA <30 YEARS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 60 NORTH AMERICA HOSPITALS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 NORTH AMERICA DIAGNOSTIC CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 62 NORTH AMERICA CANCER RESEARCH CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 63 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 64 NORTH AMERICA SPECIALIZED CLINICS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 65 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 66 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 67 NORTH AMERICA DIRECT TENDER IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 68 NORTH AMERICA THIRD PARTY DISTRIBUTORS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 69 NORTH AMERICA OTHERS IN UTERINE CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 70 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 71 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 72 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 73 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 74 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 75 NORTH AMERICA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 76 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 77 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 78 NORTH AMERICA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 79 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 80 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 81 NORTH AMERICA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 82 NORTH AMERICA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 83 NORTH AMERICA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 84 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 85 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 86 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 87 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 88 NORTH AMERICA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 89 NORTH AMERICA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 90 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 91 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 92 NORTH AMERICA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 93 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 94 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 95 NORTH AMERICA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 96 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 97 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 98 NORTH AMERICA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 99 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 100 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 101 NORTH AMERICA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 102 NORTH AMERICA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 103 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 104 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 105 NORTH AMERICA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 106 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 107 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 108 NORTH AMERICA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 109 NORTH AMERICA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 110 NORTH AMERICA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 111 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 112 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 113 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 114 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 115 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 116 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 118 U.S. ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 119 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 120 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 121 U.S. SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 122 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 123 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 124 U.S. IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 125 U.S. TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 126 U.S. BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 127 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 128 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 129 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 130 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 131 U.S. ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 132 U.S. SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 133 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 134 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 135 U.S. ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 136 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 137 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 138 U.S. UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 139 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 140 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 141 U.S. PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 142 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 143 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 144 U.S. UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 145 U.S. LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 146 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 147 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 148 U.S. ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 149 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 150 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 151 U.S. UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 152 U.S. INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 153 U.S. PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 154 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 155 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 156 U.S. UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 157 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 158 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 159 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 160 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 161 CANADA ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 162 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 163 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 164 CANADA SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 165 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 166 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 167 CANADA IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 168 CANADA TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 169 CANADA BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 170 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 171 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 172 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 173 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 174 CANADA ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 175 CANADA SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 176 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 177 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 178 CANADA ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 179 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 180 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 181 CANADA UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 182 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 183 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 184 CANADA PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 185 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 186 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 187 CANADA UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 188 CANADA LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 189 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 190 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 191 CANADA ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 192 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 193 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 194 CANADA UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 195 CANADA INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 196 CANADA PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 197 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 198 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 199 CANADA UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 200 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 201 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 202 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 203 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 204 MEXICO ULTRASOUND SCANNING IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 205 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 206 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 207 MEXICO SYSTEMS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 208 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 209 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (UNITS)
TABLE 210 MEXICO IMAGING DEVICES IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 211 MEXICO TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 212 MEXICO BLOOD TESTS IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 213 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 214 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (VOLUME)
TABLE 215 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD)
TABLE 216 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 217 MEXICO ENDOMETRIAL CANCER IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 218 MEXICO SEROUS ADENOCARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 219 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 220 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 221 MEXICO ADENOSQUAMOUS CARCINOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 222 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 223 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 224 MEXICO UTERINE CARCINOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 225 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 226 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 227 MEXICO PRIMARY PURE SQUAMOUS CELL CARCINOMA OF THE ENDOMETRIUM IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 228 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 229 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 230 MEXICO UTERINE SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY TYPE, 2021-2030 (USD MILLION)
TABLE 231 MEXICO LEIOMYOSARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 232 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 233 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 234 MEXICO ENDOMETRIAL STROMAL SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 235 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 236 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 237 MEXICO UNDIFFERENTIATED SARCOMA IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 238 MEXICO INSTRUMENT-BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 239 MEXICO PROCEDURE BASED IN UTERINE CANCER DIAGNOSTICS MARKET, BY DIAGNOSTICS TYPE, 2021-2030 (USD MILLION)
TABLE 240 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 241 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 242 MEXICO UTERINE CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF UTERINE CANCER AND INCREASING HEALTHCARE EXPENDITURE IS EXPECTED TO DRIVE THE GROWTH OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET FROM 2023 TO 2030
FIGURE 12 INSTRUMENT BASED SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA UTERINE CANCER DIAGNOSTIC MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE UTERINE CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2022
FIGURE 15 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DIAGNOSTIC TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2022
FIGURE 19 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 23 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 26 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2022
FIGURE 27 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 30 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2022
FIGURE 31 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 35 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 36 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 37 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 38 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: BY DIAGNOSTIC TYPE (2023-2030)
FIGURE 39 NORTH AMERICA UTERINE CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
